The Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is the fourth ophthalmic product launched by Glenmark. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed ...
Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment.
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...
3d
DelveInsight's "ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report" highlights the details around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback